STADA Signs an Exclusive Commercialization Agreement with Alvotech for Seven Biosimilars in Europe

STADA Signs an Exclusive Commercialization Agreement with Alvotech for Seven Biosimilars in Europe

Shots:

  • Alvotech to receive up front with subsequent milestones for the next five years. STADA to get exclusive right to commercialize seven biosimilars in all key European markets and selected markets outside Europe
  • Alvotech will remain responsible for the development, registration and supply of the biosimilars within the EU. The collaboration will expand Alvotech’s biosimilar portfolio and strengthen its presence in the EU
  • The seven biosimilar products focus on treating autoimmunity, oncology and inflammatory diseases and ophthalmology for patients across the globe and generated $50M in sales globally

Click here to­ read full press release/ article | Ref: Alvotech | Image:  Businesswire